CDK1 and liver cancer: In spite of some earlier research findings showing CDK1 as a prominent regulator of liver cancer (Ni et al., 2019; Sun and Zhang, 2020; Hao et al., 2021; Su et al., 2023), molecular docking studies have identified treatment options such the Phellodendron and Anemarrhena drug pair (PADP) as a promising inhibitor of CDK1 (Ruan et al., 2022).